Literature DB >> 8388603

Ischemic colitis in a patient with Crohn's disease taking an oral contraceptive and an ergotamine alkaloid.

L Rutgeerts1, G Ghillebert, W Drognee, W Tanghe, P Vuylsteke, M Decoster.   

Abstract

A 22-year-old woman developed transient left-sided ischemic colitis with submucosal oedema and bleeding, six weeks after an uneventful right hemicolectomy for Crohn's disease. The thrombogenic properties of the contraceptive pill and the concomitant use of an ergotamine alkaloid were thought to be the cause of this complication in a patient at risk. An increase of procoagulant activity and underlying vascular injury has been described in Crohn's disease.

Entities:  

Keywords:  Alkaloids; Belgium; Biology; Case Histories; Contraception; Contraceptive Methods--contraindications; Developed Countries; Diseases; Ergot Alkaloids; Europe; Examinations And Diagnoses; Family Planning; Gastrointestinal Effects; Ingredients And Chemicals; Ischemia--etiology; Oral Contraceptives, Combined--contraindications; Oral Contraceptives--contraindications; Organic Chemicals; Physical Examinations And Diagnoses; Physiology; Signs And Symptoms; Treatment; Vascular Diseases; Western Europe

Mesh:

Substances:

Year:  1993        PMID: 8388603     DOI: 10.1080/17843286.1993.11718284

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  3 in total

Review 1.  Ischemic necrosis of gastric wall after long-term ergotamine pill abuse: case report and review of the literature.

Authors:  E L Papalampros; S G Salakou; E S Felekouras; C Scopa; A C Tsamandas; E Bastounis
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

2.  Ischemic colitis secondary to ergotamine use: a case study.

Authors:  Regina E Rodman; Thomas D Willson; Mark M Connolly; Francis J Podbielski
Journal:  Case Rep Gastroenterol       Date:  2011-01-05

Review 3.  Preventive health measures in inflammatory bowel disease.

Authors:  Ayokunle T Abegunde; Bashir H Muhammad; Tauseef Ali
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.